Aspirin acetylation of βLys-82 of human hemoglobin: NMR study of acetylated hemoglobin Tsurumai

Biochemical Pharmacology

Volumn 60, Issue 7, 2000, Pages 917-922

  Xu, Arron S L ^a   Ohba, Yuzo ^b   Vida, Loyda ^c   Labotka, Richard J ^c   London, Robert E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aspirin; Hb Tsurumai; Hemoglobin; NMR; Sickle cell disease

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; HEMOGLOBIN A; HEMOGLOBIN DERIVATIVE; OXYHEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN TSURUMAI; HEMOGLOBIN VARIANT; LYSINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACETYLATION; AMINO ACID SUBSTITUTION; ARTICLE; BETA CHAIN; BLOOD SAMPLING; HUMAN; NUCLEAR MAGNETIC RESONANCE; OXYGEN AFFINITY; PRIORITY JOURNAL; PROTEIN PROCESSING; SICKLE CELL ANEMIA; CHEMICAL STRUCTURE; DRUG EFFECT; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ACETYLATION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HEMOGLOBINS; HEMOGLOBINS, ABNORMAL; HUMANS; LYSINE; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR;

EID: 0034287455     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00419-6     Document Type: Article

References (33)

1. Bunn HF and Forget BG, Hemoglobin - Molecular, Genetic and Clinical Aspects, pp. 453-564. W. B. Saunders Co., Philadelphia, 1986.
2. Steinberg M.H. Management of sickle cell disease. N Engl J Med. 340:1999;1021-1030.
3. Klotz I.M., Haney D.N., King L.C. Rational approaches to chemotherapy Antisickling agents . Science. 213:1981;724-731.
4. Ranny H.M., Sharma V.S. Structure and function of hemoglobin. Willams W.J., Beutler E., Erslev A., Lichtman M.A. Hematology. 1983;353-364 McGraw-Hill Book Co, New York.
5. Shamsuddin M., Mason R.G., Ritchey J.M., Honig G.E., Klotz I.M. Sites of acetylation of sickle cell hemoglobin by aspirin. Proc Natl Acad Sci USA. 71:1974;4693-4697.
6. Klotz I.M., Tam J.W.O. Acetylation of sickle cell hemoglobin by aspirin. Proc Natl Acad Sci USA. 70:1973;1313-1315.
7. Zaugg R.H., Walder J.A., Walder R.Y., Steele J.M., Klotz I.M. Modification of hemoglobin with analogs of aspirin. J Biol Chem. 255:1980;2816-2822.
8. Ueno H., Pospischil M.A., Manning J.M., Kluger R. Site-specific modification of hemoglobin of hemoglobin by methyl acetyl phosphate. Arch Biochem Biophys. 244:1986;795-800.
9. Ueno H., Pospischil M.A., Manning J.M. Methyl acetyl phosphate as a covalent probe for anion-binding sites in human and bovine hemoglobins. J Biol Chem. 264:1989;12344-12351.
10. Xu A.S.L., Macdonald J.M., Labotka R.J., London R.E. NMR study of the sites of human hemoglobin acetylated by aspirin. Biochim Biophys Acta. 1432:1999;333-349.
11. Xu A.S.L., Labotka R.J., London R.E. Acetylation of human hemoglobin by methyl acetylphosphate. J Biol Chem. 274:1999;26629-26632.
12. Goldstein R.E., Andrews M., Hall W.J., Moss A.J. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. Multicenter myocardial ischemia research group. J Am Coll Cardiol. 28:1996;326-330.
13. Hennekens C.H. Update on aspirin in the treatment and prevention of cardiovascular disease. Am Heart J. 137:1999;S9-S13.
14. Marnett L.J. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prevent Med. 24:1995;103-106.
15. 13C]aspirin. Biochem Pharmacol. 57:1999;1233-1244.
16. Ohba Y., Yamada H., Takamatsu S., Imai K. Hb Tsurumai [β82(EF6)Lys→Gln] A new Hb variant with high oxygen affinity and erythrocytosis . Hemoglobin. 20:1996;141-146.
17. Liddington R., Derewenda Z., Dodson E., Hubbard R., Dodson G. High resolution crystal structures and comparisons of T-state deoxyhaemoglobin and two liganded T-state haemoglobins T(alpha-oxy)haemoglobin and T(met)haemoglobin . J Mol Biol. 228:1992;551-579.
18. Arnone A. X-ray diffraction study of binding of 2,3-diphosphoglycerate to human deoxyhaemoglobin. Nature. 237:1972;146-149.
19. Walder J.A., Zaugg R.H., Walder R.Y., Steele J.M., Klotz I.M. Diaspirins that cross-link β chains of hemoglobin Bis(3,5-dibromosalicyl) succinate and bis(3,5-dibromosalicyl) fumarate . Biochemistry. 18:1979;4265-4270.
20. Walder J.A., Walder R.Y., Arnone A. Development of antisickling compounds that chemically modify hemoglobin S specifically within the 2,3-diphosphoglycerate binding site. J Mol Biol. 141:1980;195-216.
21. Ohsako M., Matsumoto Y., Goto S. Transport of aspirin and its metabolites throughout human erythrocyte membrane. Biol Pharm Bull. 16:1993;154-157.
22. Kacso G., Terezhalmy G.T. Acetylsalicylic acid and acetaminophen. Dent Clin N Am. 38:1994;633-644.
23. Honma K., Nakamura M., Ishikawa Y. Acetylsalicylate-human serum albumin interaction as studied by NMR spectroscopy - antigenicity-producing mechanism of acetylsalicylic acid. Mol Immunol. 28:1991;107-113.
24. Watala C., Gwodzinski K. Effect of aspirin on conformation and dynamics of membrane proteins in platelets and erythrocytes. Biochem Pharmacol. 45:1993;1343-1349.
25. Costello P.B., Caruana J.A., Green F.A. The relative roles of hydrolases of the erythrocyte and other tissues in controlling aspirin survival in vivo. Arthritis Rheum. 27:1982;422-426.
26. Costello P.B., Green F.A. Aspirin survival in human blood modulated by the concentration of erythrocytes. Arthritis Rheum. 25:1982;550-555.
27. Chatterjeee R., Iwai Y., Walder R.Y., Walder J.A. Structural features required for the reactivity and intracellular transport of bis(3,5-dibromosalicyl) fumarate and related anti-sickling compounds that modify hemoglobin S at the 2,3-diphosphoglycerate binding site. J Biol Chem. 259:1984;14863-14873.
28. Bridges K.R., Schmidt G.J., Jensen M., Cerami A., Bunn H.F. The acetylation of hemoglobin by aspirin. In vitro and in vivo. J Clin Invest. 56:1975;201-207.
29. Berlin N.I. Erythrokinetics. Williams W.J., Beutler E., Erslev A.L., Lichtman M.A. Hematology. 1980;395-405 McGraw-Hill Book Co, New York.
30. Osamo N.O., Photiades D.P., Famodu A.A. Therapeutic effect of aspirin in sickle cell anemia. Acta Haemat. 66:1981;102-107.
31. de Furia F.G., Bunn H.F., Lu Y.S., Peterson C.M. The effect of aspirin on sickling and oxygen affinity of erythrocytes. Proc Natl Acad Sci USA. 70:1973;3707-3710.
32. Greenberg J., Ohene-Frempong K., Halus J., Way C., Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr. 102:1983;781-784.
33. Zago M.A., Costa F.F., Ismael S.J., Tone L.G., Bottura C. Treatment of sickle cell diseases with aspirin. Acta Haemat. 72:1984;61-64.